Literature DB >> 11499864

Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.

T Ikeda1, M Utsuyama, K Hirokawa.   

Abstract

The receptor activator of nuclear factor-kappaB ligand (RANKL; also known as tumor necrosis factor-related activation-induced cytokine [TRANCE], osteoprotegerin ligand [OPGL], and osteoclast differentiation factor [ODF]) is a transmembrane ligand expressed in osteoblasts and bone marrow stromal cells. It binds to RANK, which is expressed in osteoclast progenitor cells, and induces osteoclastogenesis. OPG, a decoy receptor for RANKL, also binds to RANKL, and competitive binding of RANKL with RANK or OPG is thought to regulate bone metabolism. To investigate roles of the RANKL/RANK/OPG system in pathophysiological conditions, the expression of RANKL, RANK, and OPG messenger RNA (mRNA) was analyzed in bones of aged and ovariectomized rats by means of in situ hybridization. In the control 8-week-old male and sham-operated female rat bones, the expression of RANKL mRNA was detected in hypertrophic chondrocytes of the growth plate and some periosteal and endosteal mesenchymal cells. The expression of RANK mRNA was detected in osteoclast-like cells and mononuclear cells in contact with the cortical and trabecular bones. The expression of OPG mRNA was detected in proliferating chondrocytes and osteocytes. In the 2.5-year-old rat bones, the expression of RANKL, RANK, and OPG mRNA tended to decrease except for the endosteal region. In the ovariectomized rat bones, the expression of RANKL, RANK, and OPG mRNA increased, and high expression of OPG mRNA was induced in resting chondrocytes and osteocytes. These results suggest that estrogen deficiency stimulates the RANKL/RANK/OPG system and induces OPG in cells that have been thought to be less important for bone metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499864     DOI: 10.1359/jbmr.2001.16.8.1416

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  32 in total

Review 1.  The osteocyte: an endocrine cell ... and more.

Authors:  Sarah L Dallas; Matthew Prideaux; Lynda F Bonewald
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

2.  Role of DNA methylation in the regulation of the RANKL-OPG system in human bone.

Authors:  Jesús Delgado-Calle; Carolina Sañudo; Agustín F Fernández; Raúl García-Renedo; Mario F Fraga; José A Riancho
Journal:  Epigenetics       Date:  2012-01-01       Impact factor: 4.528

3.  Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.

Authors:  Takuya Sato; Ken Watanabe; Masaaki Masuhara; Naoto Hada; Yoshiyuki Hakeda
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

4.  Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.

Authors:  Jinhu Xiong; Marilina Piemontese; Jeff D Thostenson; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Bone       Date:  2014-06-14       Impact factor: 4.398

5.  OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST.

Authors:  Giuliana Silvestrini; Paola Ballanti; Mariangela Sebastiani; Martina Leopizzi; Maura Di Vito; Ermanno Bonucci
Journal:  J Mol Histol       Date:  2007-12-20       Impact factor: 2.611

6.  Commitment to the osteoblast lineage is not required for RANKL gene expression.

Authors:  Carlo Galli; Qiang Fu; Wenfang Wang; Bjorn R Olsen; Stavros C Manolagas; Robert L Jilka; Charles A O'Brien
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

Review 7.  Control of RANKL gene expression.

Authors:  Charles A O'Brien
Journal:  Bone       Date:  2009-08-27       Impact factor: 4.398

8.  Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response.

Authors:  G J Atkins; K J Welldon; P Halbout; D M Findlay
Journal:  Osteoporos Int       Date:  2008-09-02       Impact factor: 4.507

9.  The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.

Authors:  Inaam A Nakchbandi; Robert Lang; Barbara Kinder; Karl L Insogna
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

Review 10.  Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures.

Authors:  L M McNamara
Journal:  J R Soc Interface       Date:  2009-10-21       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.